Circulating tumor DNA predicts recurrence in early-stage triple-negative breast cancer

SAN ANTONIO — Detection of circulating tumor DNA after neoadjuvant chemotherapy appeared to independently predict disease recurrence among women with early-stage triple-negative breast cancer, according to preplanned analyses of results from the randomized phase 2 BRE12-158 trial presented at San Antonio Breast Cancer Symposium.“We are obviously very excited by these findings,”

Read the full article here

Related Articles